rilzabrutinib
rilzabrutinib is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including WAYRILZ. Available dosage form: tablet, film coated.
Drug Details
- Generic Name
- rilzabrutinib
- Brand Names
- WAYRILZ
- Application Number
- NDA219685
- Sponsor
- Sanofi S.r.l.
- NDC Codes
- 2
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- RILZABRUTINIB
Indications and Usage
1 INDICATIONS AND USAGE WAYRILZ is indicated for the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. WAYRILZ is a kinase inhibitor indicated for the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. ( 1 )